CD8A and neoplasm: Combining Tubastatin A (an HDAC6/8‐selective inhibitor) with acetate increases H3K27ac signal, markedly up‐regulates core TRM markers including CD103 and CD69, and enhances the tissue‐residency capacity of virus‐ or tumor‐specific CD8+ T cells [92].